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MOLECULAR MECHANISM OF XY GONADAL 
DYSGENESIS  
Griendy Indig-Weingarten 
One of the fundamentals of human sociology is the characterization of the 
people around us based on gender.  We tend to think of gender as a strict binary 
system where the option is clear: boy or girl. Although society usually honors this 
dichotomy, biology allows more flexibility to the definition of male versus female. 
Estimates state that one in every 2000 births is one with a disorder of sex development 
(The Intersex Society of North America 2006). Some of the disorders are visually 
obvious while others are only discovered later on in life. Regardless of when the 
disease first becomes obvious, all of these disorders constitute a variation along the 
standard development of a male or female. Therefore, to understand disorders of sex 
development, one must first understand what constitutes normal sex development. As 
in all of embryology, development is controlled by many different genetic codes and 
the pathways they encode. Therefore, variation along any gene responsible for any 
part of the sex differentiation mechanism will result in a deviation from the expected.  
NORMAL SEX DEVELOPMENT 
The identity of the sperm that successfully penetrates the ovum is the official 
beginning of sex determination. When meiosis of the spermatocyte is completed, the 
mature haploid spermatozoa can either have an X or a Y as its twenty-third 
chromosome. When this particular sperm penetrates the ovum, the identity of its 
twenty-third chromosome determines the genetic sex. This is the first step of sex 
determination. Further sex development is divided into two parts: primary sex 
determination and secondary sex determination. Primary determination involves the 
development of the fetus’s gonads. Once formed, the gonads start producing hormones 
which initiate secondary sex development. Secondary sex development includes the 
development of duct systems and external genitalia. Secondary sex development is 
only complete after puberty (Gilbert 2010). 
PRIMARY SEX DIFFERENTIATION 
Regardless of their karyotype, initially all embryos present a common set of 
genital structures. These include the gonads, the internal duct system, and the external 
genitalia. The development of the genital system begins at the fourth week of 
embryonic life. The entire genital system is derived from the intermediate mesoderm 
and urogenital sinus except for the gametes which emigrate from the mesoderm of the 
yolk sack. The intermediate mesoderm differentiates to form the adrenal cortex and 
the start of the urogenital ridge originating as the nephrogenic cord. The urogenital 
ridge is the site of the development of the urinary and reproductive system. The 
cephalic portion of the nephrogenic cord further matures to form the pronephros, 
which is mostly an embryonic structure. The more caudal portions of the nephrogenic 
cord form the mesonephros and the pronephric duct which later forms the 
mesonephric duct. The genital ridge arises along the middle portion of the 
mesonephros. This is the central location for the development of the gonadal and 
genital structures. The caudal (posterior) portion of mesonephric duct fuses with 
mesonephric tubules and continues to extend and connect to the urogenital sinus.  
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Then the most caudal 
area of the nephrogenic 
ridge further develops 
into the metanephros 
which is the permanent 
kidney (Figure 1) 
(McMahon et al. 2008).   
GONADS 
The gonads are 
unique embryonic 
structures because they 
are the only bipotential organs. They can develop into ovaries or testes. Gonads 
usually appear at week four but remain undifferentiated until week seven. At about 3-4 
weeks, the mesonephros is at its largest size, and it is at this point that the epithelial 
layer of the mesonephros, also known as the coelomic epithelium, starts to proliferate 
into the surrounding mesenchyme, or undifferentiated loose connective tissue, and 
form the primary sex cords. These cords will surround the entering germ cell to form 
the gonadal cord. At this point, the gonadal tissue will start to differentiate to testes or 
ovaries. 
MALE GONADAL DEVELOPMENT  
An XY fetus, at around the eighth week, will start developing testicular tissue. 
This begins with the differentiation of the gonadal cord into the Sertoli supporting 
cells. These cells form processes that surround the primordial germ cells and 
eventually mature into Sertoli cells. At the same time, cells migrating from the 
mesonephros, called peritubular myoid cells, form a single layer around the gonadal 
cords. These peritubuluar myoid cells contribute to the structural integrity of the testis 
cord and will support spermatogenesis later in the adult male’s life (Buehr et al. 1993). 
It is at this point (around the eight week) that the gonadal cord is recognizable as the 
first form of the testis cord. The testis cord then comes in contact with the mesonephric 
tubules which are connected to the mesonephric duct, causing a capsule called the 
tunica albuginea to form around the testes. Meanwhile, the testis cords continue to 
create a dense network called the rete testis. The rete testis functions later on as the 
carrier of sperm from the seminiferous tubules out of the testicles through the efferent 
duct which was derived from the mesonephric tubules. At 20 weeks, the testis cord 
forms the straight and convoluted seminiferous tubules. The straight tubules are 
connected to the rete testis and do not have any germ cells within them. The 
convoluted tubules are a continuation of the seminiferous tubules and contain the 
primordial germ cells. Spermatogenesis takes place in the convoluted tubules (Celio et 
al. 1999). Once the testis is formed, some primordial germ cells differentiate into a pre-
sperm state called T1-prospermatogonia and remain that way until puberty (Gilbert 
2010). 
Another important part of testicular development is the differentiation of the 
Leydig cells. These cells originate from mesenchyme, or the undifferentiated loose 
connective tissue in between the testis cords. These Leydig cells eventually produce 
testosterone which will be crucial to further male differentiation. Because of its steroid 
Figure 1: Nephrogenic Cord.  
Source: http://vanat.cvm.umn.edu/TFFlectPDFs/LectEmbUrinarySys.pdf. 
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producing nature, Leydig cells tend to cluster near the testicular vasculature (Wilhelm 
2007). 
FEMALE GONADAL DEVELOPMENT  
In the case of an XX embryo, the gonads usually develop into ovaries. The 
ovaries start developing during the eight week. In the absence of testis determining 
genes, the genital ridge will differentiate into ovaries. However, unlike testis, in which 
the testis cord forms early on in embryogenesis, the functional unit of the female 
gonads—the ovarian follicles—completely mature only at puberty. During fetal 
development, primordial follicles are formed.  These follicles are usually formed 
around 16-24 weeks after fertilization (Celio et al. 1999). The ovarian development 
begins with the migration of the primordial germ cells into the genital ridge and the 
gonadal cord partially atrophies. Later on, the primordial germ cells proliferate and 
form the primordial oocyte, or the oogonium. At around the fifth month, the oogonia 
are arrested at prophase of the first meiosis and are subsequently surrounded by 
pregranulosa cells which differentiated from the gonadal cord. These granulosa cells 
are connected with cellular bridges and high levels of vasculature. One of the key 
differences between the male and female primordial germ cells is that while all the male 
cells will continue to proliferate and mature to sperm from the age of puberty 
throughout a lengthy adult life, only the female cells that have matured and were 
arrested at prophase of the first meiotic division in utero will mature into ooctyes.  
MOLECULAR GENETICS OF GONAD DEVELOPMENT 
TESTIS PATHWAY 
 Genetic sex is defined as the presence of an XX or XY karyotype. In either 
case, one X will be inactivated, allowing the X or the Y to be the defining chromosome 
in sex determination. The Y chromosome carries a dominant testis-determining gene 
which actively promotes testicular development. Absence of the gene, regardless of the 
identity of the rest of the chromosome, will cause the embryo to go into “default” 
development and continue to develop as a female. It is for this reason that sex 
determination is sometimes equated with testis determination. This was proven by 
Alfred Jost when he castrated rabbits in utero and the rabbits’ development continued 
according to the female pattern (Jost 1972). Later research showed the testis-
determining gene to be the SRY gene on the short arm of the Y chromosome. In fact, 
the research that discovered the connection between the SRY gene and testis 
determination was carried out on XY females and Turner Syndrome patients (Berta et 
al. 1990). 
SRY: SEX- DETERMINING REGION Y 
The SRY gene is located on the upper short arm of the Y chromosome. In 
studies using XX reversed males and XY reversed females, results showed that a fetus 
with the Y short arm, even when missing the long Y arm, would develop testis. 
Accordingly, any individual missing the Y short arm would not develop testis. 
Additionally, if the SRY gene is inserted in the genome of a normal XX mouse, the XX 
mouse would develop testis (Koopman et al. 1991). The SRY gene is expressed in the 
bipotential gonads immediately before differentiation of the Sertoli cells begins, at 
around eight weeks, and is deactivated a few days later (Cotinot et al. 2002). Although 
SRY is deactivated after a short window, while active, it synthesizes the SRY 
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transcription factor whose primary role is to activate the SOX9 gene, allowing 
differentiation to continue even after SRY is deactivated. 
SOX9 
The SOX9 gene is located on the seventeenth chromosome. SOX genes are 
called transcription factors due to their nature of transcribing proteins that can bind to 
specific locations on DNA to control gene activity. SOX9 is involved in many 
developmental processes, particularly skeletal formation. In fact, the role of SOX9 in 
testis formation was discovered when a link between SOX9 and a condition called 
campomelic dysplasia was discovered. Campomelic dysplasia patients exhibit multiple 
skeletal abnormalities.  Interestingly enough, however, 75% of the 46 XY patients with 
campomelic dysplasia were sex-reversed females (Cooke et al. 1985). This led 
researchers to discover that when SOX9 is activated in the genital ridge, it induces 
testis formation. Studies have shown that mice missing the SRY gene but possessing an 
extra copy of the SOX9 will develop as male. Accordingly, mammals possessing the 
SRY gene but lacking the SOX9 gene will not develop male (Huang et al. 1999).  
SOX9 works in several different manners: 
• It activates its own promoter, creating a positive feedback loop which allows it 
to be active for a longer period of time (Sekido and Lovell-Badge 2008). 
• It blocks genes that are involved in ovary formation (de Santa Barbara et al. 
2000).  
• It can bind and activate different genes necessary for testicular development. 
• It promotes the gene expression necessary to produce fibroblast growth factors 
that are critical for Sertoli Cells precursors.  
• It binds to the gene that promotes the production of anti-mullerian factor (de 
Santa Barbara et al. 2000).  
SOX9 is detected in 
the somatic cells in the 
human fetal gonads as early 
as the sixth week. When the 
Sertoli cells start 
differentiating, SOX9 is 
expressed in the nuclei of 
the cells (de Santa Barbara 
et al. 2000).  Studies done 
on SOX9 have found that it 
very often works together 
with a nuclear receptor 
called steroidogenic factor-1 
(SF-1) which is activated 
by the NR5A1 gene. The 
relationship between the 
SRY, SOX9, and SF1 is 
explained in Figure 2.     
NR5A1 
NR5A1 is sometimes 
referred to as the SF-1 gene 
In the cytoplasm, SRY is bound by 
calmodulin (CaM) and importin & 
(Imp&), which recognize the N- and 
C-terminal nuclear localization 
signals (NLSs) on SRY, respectively, 
and recruit it to enter the nucleus. At 
10.5 dpc, SRY and steroidogenic 
factor 1 (SF1) bind directly to 
specific sites (`TESCO', testis-
specific enhancer of Sox9 core) that 
lie within the gonadal specific 
enhancer of Sox9 (indicated by the 
coloured regions on the DNA) and 
upregulate Sox9 expression 
cooperatively. At 11.5 dpc, after 
initiation of Sox9 expression, an auto-
regulation system operates in which 
SOX9 also binds directly to TESCO 
with SF1 to prolong and amplify Sox9 
expression. Abbreviations: SOX9, 
SRY box containing gene 9; SRY, 
sex-determining region on the 
chromosome Y. 
 Figure 2: Cellular mechanism of SRY function. Source: 
http://dev.biologists.org/content/137/23/3921.full 
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because it encoded the SF-1 receptor. The NR5A1 gene spans seven exons and is 
located on the ninth chromosome (Johns Hopkins University School of Medicine 
2011). It functions in gonadal differentiation and in steriodogenesis. Knockout mice 
(mice that were genetically altered) missing the NR5A1 gene developed with complete 
adrenal and gonadal agenesis. Studies show that SF-1 is involved early in 
embryogenesis during development of the bipotential gonad. Although it is not 
completely understood how SF-1 functions in the embryogenetic stage, mice missing 
the part of the NR5A1 gene that encodes for SF-1 never developed a genital ridge. SF-1 
is already active in humans at four weeks when the gonadal ridge starts to form, and its 
levels remain high in the testis even once the SRY shuts off. SF-1 aids in activating 
SOX9 and continues to work with SOX9 to elevate the anti-mullerian hormone 
transcription. As the name steriodogenic indicates, SF-1 is involved in hormone 
production. It is involved in multiple steroid-producing functions, such as 
collaborating with SOX9 to produce AMH (anti-mullerian hormone), and activating 
genes involved with testosterone production in Leydig cells (Shen et al. 1994). Mice 
lacking the SF-1 gene lack both adrenal glands and gonads, proving that the SF-1 gene 
is involved in early embryogenesis of the urinary and reproductive system (Luo et al. 
1994). 
OVARY PATHWAY 
In order to provide a complete picture of development, the molecular pathway 
of the ovaries is briefly discussed, although these genes are not involved in XY 
Gonadal Dysgenesis.  
WNT4  
Early on, WNT4 is expressed in the genital ridge in both male and female 
embryos. However, its expression, while still maintained in the fetal ovaries, is 
undetectable in the fetal testes. Mice that lack the gene will fail to develop ovaries 
(Cotinot et al. 2002).  
R-SPONDIN-1 
Another critical gene is R-spondin-1, a protein expressed by RSPO1. An XX 
fetus with gene mutation in RSP01 will be XX male. RSPO1 acts together with WNT4 
to produce beta-catenin, which activates further ovarian development, and block SOX9 
production. An XY fetus with a duplication of the WNT4 and RSPO1 on its 
chromosome will develop ovaries instead of testis (Gilbert 2010).  
(There are many other genes involved in both testis development and ovarian 
development that are not discussed in this paper.) 
SECONDARY SEX DEVELOPMENT  
Once the gonads are formed, they start to produce hormones. These hormones 
are initiators of secondary sex development. Once these hormones begin to be 
secreted, secondary sex development can start. It is important to note that primary and 
secondary developments do overlap, as the testes and ovaries continue to develop once 
steroids are produced. 
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INTERNAL DUCT SYSTEM  
The gonads are just one part of the 
sex differentiation process. The ducts 
system, like the gonads, start out in an 
undifferentiated state. In the 
undifferentiated stage, the embryo presents 
with mesonephric ducts, also known as the 
Wolffian ducts. Paramesonephronic ducts, 
which appear in the sixth week, form part 
of the urogenital cord. The Wolffian ducts 
form from the nephrogenic cord and 
develop toward the cloaca. Mesonephric 
tubules, another part of the mesonephros 
involved in the development of the internal 
ducts, arise from the mesenchyme of the 
mesonephros and eventually fuse with the 
mesonephric duct to create a passage to the 
cloaca (Schoenwolf et al. 2009). The Mullerian Duct is formed when the coelomic 
epithelium, near the top of the mesonephros, invaginates. Both the Mullerian and the 
Wolffian ducts continue to grow caudally towards the urogenital sinus (Figure 3) 
(Sweeney 1998 ). 
MALE DUCT SYSTEM DEVELOPMENT  
During early embryogenesis, the Wolffian duct serves as an excreting duct for 
the mesonephros. Once the metanephros becomes functional, most of the mesonephric 
duct atrophies, and the part that remains is dependent on the testosterone released 
from the Leydig cells in the fetal testis. In the eighth week of gestation, the Leydig cells 
start releasing testosterone and thus begin two important aspects of the internal male 
duct system development. One is the atrophying of the paramesonephric duct, and the 
other is the further development of the mesonephric duct (Celio et al. 1999).  The 
undifferentiated state includes both sets of ducts, and with the start of duct 
differentiation, the paramesonephric duct starts to atrophy due to the effect of anti-
mullerian hormone released by the Sertoli cells within the seminiferous tubules. It is 
interesting to note that a small part of the paramesonephric duct does remain and 
differentiates into the appendix testis (Jacob and Barteczko 2005). Meanwhile, the 
Leydig cells begin releasing testosterone to support the development of the 
mesonephric duct. Most of the top portion of the Wolffian duct atrophies, leaving only 
the portion which differentiates into the efferent duct, epididymis, vas deferens, and 
seminal vesicles.  
FEMALE DUCT SYSTEM DEVELOPMENTS 
In a human embryo, the absence of the anti-mullerian hormone causes the 
undifferentiated ducts to develop into the female duct system. The mesonephric ducts 
and tubules atrophy, and the paramesonephric duct further develops. In the eighth 
week, the two lower portions of the mullerian duct fuse. This fused portion is the site 
of the uterus. The upper portion of the paramesonephric duct proliferates outwards 
towards the gonad and develops as the fallopian tubes. The lowest portion forms the 
utero-vaginal canal (Celio et al. 1999).  
Figure 3: Internal Duct System 
1-Mesonephros 
2-Paramesonephric Duct 
3-Mesonephric Duct 
4-Indiffernt Gonads 
5-Urogenital Sinus  
Source: Celio et al. 1999. 
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EXTERNAL GENITALIA DEVELOPMENT 
The external genitalia arise from the genital tubercle, the urogenital groove and 
sinus, and the labioscrotal fold.  
 As opposed to male development where testosterone plays a key role in 
differentiation, estrogen is not involved in female sexual differentiation. Instead, it is 
produced by the ovaries to function as support for follicular maturation. In fact, both 
male and female fetuses are exposed to high amount of estrogen from their mother. 
The embryo has a predisposition to develop internal female duct systems (fallopian 
tubes and uterus), so unless there is an active intervention by anti-mullerian hormone 
(secreted by Sertoli cells) and testosterone (secreted by the steroidogenic Leydig cells) 
to promote development of the epididymis, vas deferens, efferent ducts, and other male 
organs, a female system will develop. Furthermore, male external genitalia are 
dependent on specific hormonal activity. The undifferentiated embryo is very rich in 
androgen receptors. Once the Leydig cells start producing androgen, particularly 
dihydro testosterone, the male external genitalia develop, first into a phallus, and then 
further into the mature penis, phallic urethra, and scrotum. The absence of androgen 
causes the development of the clitoris, urethra, vagina, and labia. This further 
demonstrates that male external genitalia formation requires active intervention 
(Schoenwolf et al. 2009). This is why it is said that an embryo, if left to its own 
devices, will go to “default development” and develop female. 
This concludes a summary of sex differentiation (Figure 4). Most discoveries of 
the mechanisms involved in this development were discovered when studying patients 
with an abnormal sex development or disorder of sex development. 
DISORDERS OF SEX DEVELOPMENT 
Disorders of sex development are defined as any congenital condition in which 
development of chromosomal, gonadal, or anatomical sex is atypical (The Intersex 
Society of North America 2006). As seen earlier, sex differentiation is a complex and 
lengthy process, involving many different genomic pathways. As a result, there are 
many different variations along the developmental process which can cause atypical 
presentation. If a mutation exists which impedes the development of one of the 
necessary functions, it is expected that an abnormal phenotype will occur. Disorders of 
sex development is a very broad term which spans a spectrum of various different 
phenotypical presentations. The defining factor in determining the outcome of a 
variation depends on which point of development it affects. The first step of sex 
differentiation is genetic sex. Examples of disturbances in the proper genetic sex 
Figure 4:  Timeline of the primary and secondary sex development. Source: 
http://www.embryology.ch/images/imagegraphe/u1e_schemdifferentEn.gif. 
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development are Turners Syndrome (45 XO female), Klinefelters Syndrome (47 XXY 
male), XYY syndrome, and a few others. The next step in sexual determination is 
gonadal sex. Disorders of gonadal sex include XX Gonadal Dysgenesis and XY 
Gonadal Dysgenesis. The final part of sex development is anatomical sex. Variations in 
anatomical sex are the broadest of the three steps of sex development. Conditions 
range from phenotypical female, ambiguous genitalia, and phenotypical male. These 
conditions include congenital adrenal hyperplasia, androgen insensitivity syndrome, 
hypospadias, 5-alpha-reductase deficiencies, and many others (The Intersex Society of 
North America 2006).  
XY GONADAL DYSGENESIS 
One of the defining moments in male or female sex differentiation is the identity 
of the mature undifferentiated gonad. Once the gonad has differentiated to either testis 
or ovary, it initiates steroidogenic activity which will define the rest of the anatomical 
development. If gonadal development were to halt at the stage of indifference, such an 
occurrence would be called XY gonadal dysgenesis. The term gonadal dysgenesis 
involves the broader group of conditions that would cause the dysgenesis, or failure to 
develop, of the gonads. In Turner Syndrome, gonadal development fails due to a 
monosomy of the sex chromosome; the gonads are missing crucial genes for gonadal 
development. In a condition known as XX gonadal dysgenesis, gonads which should 
develop into ovaries are missing ovarian defining genes or receptors to complete 
ovarian development. Perhaps the most fascinating is that of an XY fetus developing 
phenotypically as a female due to gonadal dysgenesis in a condition called XY gonadal 
dysgenesis (Sinclair and Cameron 2004).  
CLINICAL PRESENTATION 
XY Gonadal Dysgenesis is usually diagnosed when a patient who failed to 
develop secondary female sex characteristic undergoes testing to determine the cause. 
The patient usually presents a female phenotype but no or sparse pubic and underarm 
hair, no or little breast tissue development, and amenorrhea. Examinations and 
ultrasound images reveal usual female external genitalia, fallopian tubes, and uterus 
but no visible ovaries. The incidence of occurrence is hard to estimate, with some 
papers stating numbers as frequent as 1:30,000 and others quoting numbers as low as 
1:150,000 (Wilhelm 2010).  
TREATMENT 
Although XY Gonadal Dysgenesis is not a diagnosis that comes along with 
serious medical conditions (except in gene specific abnormalities that will be discussed 
later), it does come along with some medical aspects that need to be addressed.   
HORMONE REPLACEMENT THERAPY (HRT) 
One option is to substitute the hormones that the patient is missing due to the 
dysfunctional gonads. Patients with XY Gonadal Dysgenesis need to start hormone 
replacement therapy to initiate pubertal development, and they need to remain on the 
therapy to maintain optimal health. The doctor will usually start off the patient on a 
low dosage of estrogen, most often in the form of a 0.3 mg tablet of premarin, a form of 
estrogen. The dose will increase over a span of 2-3 years. The incremental increase is 
intended to mimic the hormonal activity that normally would take place at the start of 
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puberty. During this time, all the expected secondary sex characteristic should 
develop. 
 Because the uterus is also maturing during this time, it is important to initiate 
menstruation with progesterone to reduce the risk of uterine cancer. A doctor will 
usually recommend bringing on a menses a minimum of four times a year for the 
upkeep of optimal uterine health. There are a number of different forms of HRT: 
tablets, patches, gels, injections, and implantable pellets. Some health professionals 
recommend taking a combined form of estrogen and progesterone, and some add a low 
dose of testosterone to more accurately mimic the natural hormone production in 
healthy females. There are conflicting reports as to what form and dose is optimal, and 
most patients find that the process to find the right regimen depends on what works 
best for them personally (WebMD 2009).  
GONADECTOMY  
Patients with XY gonadal dysgenesis must undergo a gonadectomy, surgery to 
remove the streak gonads so that they do not develop into dysgerminomas (germ cell 
tumors). The risk of an XY gonadal dysgenesis patient developing cancer is estimated 
at around 30% occurrence rate, which is why doctors recommend that gonadectomy 
be preformed soon after diagnosis. Dysgerminomas can develop in adults with streak 
gonads due to their indifferent embryonic structures which are not intended to be 
mature organs. The gonadal tissue of the 
streak gonads contains germ cells and many 
pre-Sertoli/granulose cells scattered 
throughout the stroma. These cells can 
develop into gonadoblastomas, benign 
neoplasms, exclusive to these types of cells. 
These neoplasms can become malignant and 
form dysgerminomas and other malignant 
growths (Michala et al. 2008). Cases have 
been reported in which patients as young as 
nine months have developed dysgerminomas 
(Dumic et al. 1993); therefore doctors 
recommend removing the gonads as early as 
possible. With the advances of modern 
surgical techniques, most gonadectomies are 
done laparoscopically and involve minimal 
recovery with little scarring (Figure 5).  
GENETIC CAUSES OF XY GONADAL DYSGENESIS 
Five genes have been identified in relation to XY gonadal dysgenesis. Because 
of the rarity of the condition and the constantly developing field of molecular genetics, 
many of their mechanisms are poorly understood. 
SRY 
Mutations in the SRY gene (the testis-determining gene) have been found in 10-
15% of all XY Gonadal Dysgenesis. Most mutations are in the HMG (High Mobility 
Group) box on the SRY gene. The HMG box is capable of sequencing specific DNA 
binding and bending. This is crucial in the SRY gene, because it is the specific bending 
pattern which activates the SRY in the gonads. The bends act by changing the 
Figure 5:  Laparoscopic removal of streak 
gonads (indicated by the white arrows) in 
patient with XY Gonadal Dysgenesis.  
Source: 
http://radiographics.rsna.org/content/28/7/1891
/F14.large.jpg 
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chromatin structure in the regulatory region of the target gene that starts the assembly 
of the regulatory complex. The identification of HMG as the critical region was 
formed when researchers noticed that there are variations in the non-HMG portions of 
the SRY nucleotide sequences which do not have any effect on testicular development. 
This finding demonstrated that these regions are not involved in testis development. As 
previously mentioned, SRY is expressed in the genital ridge for a brief time, stimulating 
Sertoli cell and testis determination (Sinclair and Cameron 2004). A few factors have 
been identified as regulators for SRY. The WT1 may activate SRY through an SRY 
promoter region which it expresses. It is also hypothesized that the SRY gene itself 
might have a transcription site on it for auto regulation (Vilain et al. 1992). The roles 
identified in SRY include the induction of the mesonephric cells into the ridge to form 
the testis cord, proliferation of the cells, and inducement of Sertoli cell differentiation. 
The lack of SRY also causes the failure of the SOX9 and any other gene relying on SRY 
as its regulatory “switch.”  
SRY related XY gonadal dysgenesis has been observed in familial lines, but 
most cases are de novo mutations which cause the loss of binding and its subsequent 
failure to initiate testis differentiation. Although SRY is expressed in somatic cells in 
different areas in the body, no other effects have been observed as a result of the SRY 
mutation (Simpson 2008). 
DHH 
DHH, the desert hedgehog gene, is located on the twelfth chromosome and is 
composed of three exons. DHH expression was observed in the testis of fetal mice. In 
the ovaries of fetal mice, however, little DHH expression was observed. This led to the 
initial belief that DHH is involved in testis development. The product of the DHH is 
found in Sertoli cells and in Schwann cells. Therefore, patients with DHH mutation 
usually have polyneuropathy (many nerves acting simultaneously). Unlike SRY which 
directly affects Sertoli cell development, DHH affects the development of different cells 
called peritubular myoid cells, which are cells that make a thin lining around the testis 
cord. Interruption of peritubular cell proliferation will cause a failure in the 
development of the testis cord, which will cause a failure in gonadal development. In 
fact, DHH-deficient knockout mice showed male sterility, peritubular defects, and 
testis-development failure. In addition to its role in testis cord development, studies 
suggest that the DHH is a regulator signal for the differentiation of Leydig cells in the 
fetal testis and is also involved in upregulating the SF-1 factor (Canto et al. 2004).   
Patients with DHH mutation may have complete or partial Gonadal Dysgenesis. 
Partial gonadal dysgenesis usually presents itself with slightly masculinized external 
genitalia and some internal male ductal development. Some development does occur, a 
result of some androgen production, usually due to a mosaic presentation, meaning 
that not all cells have the mutation of the DHH gene. In complete gonadal dysgenesis, 
most patients posses homozygous mutations which do not allow any DHH expression 
to reach the threshold for testicular development.  
DHH is also expressed in Schwann cells along peripheral nerves. Therefore, 
mutations in DHH can cause a condition called polyneuropathy. Polyneuropathy is a 
neurological disorder which causes many nerves to malfunction simultaneously. 
Impaired nerve transmission occurs due to reduced insulation of nerves by the affected 
Schwann cells (Canto et al. 2004). DHH-related gonadal dysgenesis is estimated to 
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account for 20% of all complete gonadal dysgenesis cases and 50% of all partial 
gonadal dysgenesis cases. 
NR5A1 (SF-1) 
NR5A1 encodes the SF-1 (steroidogenic factor-1) and is sometimes referred to 
as the SF-1 gene. It is a nuclear receptor that binds to and regulates the transcription 
of many target genes involved in gonadal and adrenal development. SF-1 was first 
studied in XY gonadal dysgenesis patients displaying complete adrenal failure. This 
was a direct indication of the role SF-1 plays in the formation of both gonadal and 
adrenal glands. These patients had homozygous mutations and did not have any SF-1 
expression.  In most human studies, it is rare to find a patient with complete 
adrenogonadal failure due to NR5A1. Later studies dealt with patients with 
heterozygous missense and frameshift mutation affecting only parts of the gene. These 
patients presented little or no adrenal failure. Many of these patients displayed 
androgen biosynthesis failure and impaired leydig cell development. Some even 
presented testicular tissue development (Achermann et al. 2002). This highlighted the 
fact that SF-1 acts within a dose-dependent function as opposed to acting as an on and 
off switch. 
The prevalence of NR5A1 XY gonadal dysgenesisis low. 
CBX2 
A fourth gene whose mutation can cause XY Gonadal Dysgenesis is the 
Chromobox homolog protein 2 (CBX2). The CBX2 gene is part of   Polycomb 
Recessive Group 1 on the seventeenth chromosome, which encodes polycomb group 
proteins. These proteins form large protein complexes capable of chromatin 
remodeling on primordial germ cells. Chromatin remodeling initiates the transition 
from mitotic division early in embryogenesis to meiosis once they are in a specific 
gonad. Research also indicates that the CBX2 might have a role as a promoter of the 
SF-1 (Baumann and De La Fuente 2011).  Knockout mice missing the CBX2 gene 
expressed skeletal abnormalities and sex reversal (Lauber et al. 2009). 
DMRT1/ 9P DELETION 
Deletion of the tip of the 9p chromosome is associated with gonadal dysgenesis. 
This association, however, was discovered quite recently, so most research is still based 
on presumption. Because the deletion of the tip of 9p affects a number of 
chromosomes, patients present with complex phenotypic features including ambiguous 
genitalia and craniofacial abnormality. Deletion of the DMRT1 gene, located on the 
ninth chromosome, has been identified as a cause of XY gonadal dysgenesis. DMRT1 is 
unregulated in the genital ridge and is, therefore, linked to testis development. 
Research shows that DMRT1 is critical for maintaining the activity of other male 
differentiation genes like SOX9. It is a sequence-specific transcriptional regulator, 
meaning that it will regulate the transcription of other genes. In this case, it is likely 
that it binds to NR5A1 and promotes SF-1 production to upkeep the continued gene 
expression of SOX9. Loss of the DMRT1 gene in mice, even after undergoing complete 
male development, can cause reversal of the Sertoli cells into granulose cells by 
promoting the production of female promoting genes. In humans, this deletion does not 
result in female development as is does in mice, but it does halt male development, 
causing XY gonadal dysgenesis (Matson et al. 2011). 
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CONCLUSION 
With the discovery of sex chromosomes in 1921, the scientific world anticipated 
that the genetics of male and female differentiation would become clearer. However, it 
was not until the 1990s that the SRY gene was discovered when XY females were 
studied. The study of XY females also revealed other genes involved in the different 
aspects of sex differentiation. The connection between DHH and the development of 
the peritubular myoid cells is evident in patients with XY gonadal dysgenesis due to a 
mutation of the DHH gene. NR5A1 plays a crucial role in encoding the steriodogenic 
factor-1 which plays multiple roles in gonadal cord development and further 
differentiation of the testis. Another gene mutation in XY gonadal dysgenesis patients, 
a mutation in CBX2, provides insight into its role in regulation of primordial germ cell 
development. Studying the role of DMRT1 in regulating continued male differentiation 
helps scientists gain a deeper understanding of the mechanisms involved in testicular 
development.  
Science is constantly evolving, and research conducted on patients with XY 
gonadal dysgenesis and other disorders of sex development will further the 
understanding of the different components of male differentiation and development.  
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